DKTK-Studienregister

DetailsucheDetailsuche
Klicken Sie auf Detailsuche, um z.B. nach Therapielinie, molekularem Marker oder Rekrutierungsstatus zu suchen.
FreitextsucheFreitextsuche
Sie können hier nach dem Studienkurzcode oder einem Teil des Studientitels suchen.
Studienauswahl
Zentren
Status der Studie

» Neuroonkologie » Glioblastom (WHO Grad IV)

Erstlinie

Glio-XS15
Multi Peptide Vaccination With XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma (Aktiv)

INTRAGO II
A multicenter randomized Phase III Trial in INTraoperative RAdiotherapy in newly diagnosed GliOblastoam multiforme (INTRAGO II) (Aktiv)

NOA-20
In this trial patients with newly diagnosed glioblastoma with an unmethylated MGMT-promoter are treated with targeted substances according to the results of a molecular and genomic characterization of their tumor tissue. One out of 8 drugs is given to the patient in combination with radiotherapy. (Aktiv)

PETra (STR)
Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma Multiforme (Aktiv)

RESURGE
Surgery for Recurrent Glioblastoma (RESURGE) (Aktiv)

Zweitlinie oder später

Basilea
Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma (Aktiv)

CDI-CS-002
Phase 1/2a Studie zu BAL101553 als Zweitlinientherapie bei rezidivierenden/progressiven Hirntumoren (Aktiv)

Car2Brain
Intracranial Injection of NK-92/5.28.z (HER2.taNK) Cells in Patients With Recurrent HER2-positive Glioblastoma (Quilt 3.C001) (CAR2BRAIN) (Aktiv)

EOGBM1-18
First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma (Aktiv)

GlioCave - NOA-17, RadOnc MRI TUM - 1
Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma (Aktiv)

HIT-HGG-Rez-Immunovac
Autologous Dendritic Cells and Metronomic Cyclophosphamide for Relapsed High-Grade Gliomas in Children and Adolescents HIT-HGG-Rez-Immunovac - A Clinical Phase I/II Trial of the HIT-HGG Study Group - (Aktiv)

RESURGE
Surgery for Recurrent Glioblastoma (RESURGE) (Aktiv)

VXM01-AVE-04-INT
An open-label, Phase I/II multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma following standard treatment with or without second surgery. (Aktiv)

DKTK-Studienregister
Dr. N. Gökbuget, Dipl.-Biol. K. Ihrig | Ohne Gewähr für Richtigkeit oder Vollständigkeit | ccp@dkfz.de